Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2015 | Pages:
236 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Wounds - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Wounds - Pipeline Review, H2 2015', provides an overview of the Wounds's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wounds, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wounds and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Wounds - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wounds and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wounds products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wounds pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wounds - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Wounds pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Wounds Overview 11 Therapeutics Development 12 Pipeline Products for Wounds - Overview 12 Pipeline Products for Wounds - Comparative Analysis 13 Wounds - Therapeutics under Development by Companies 14 Wounds - Therapeutics under Investigation by Universities/Institutes 20 Wounds - Pipeline Products Glance 23 Late Stage Products 23 Clinical Stage Products 24 Early Stage Products 25 Unknown Stage Products 26 Wounds - Products under Development by Companies 27 Wounds - Products under Investigation by Universities/Institutes 32 Wounds - Companies Involved in Therapeutics Development 34 Advancell 34 Aerpio Therapeutics, Inc. 35 AlgiPharma AS 36 AndroScience Corporation 37 AnGes MG, Inc. 38 Aridis Pharmaceuticals LLC 39 Beech Tree Labs, Inc. 40 Berg LLC 41 Bio3 Research S.r.l 42 Biokine Therapeutics Ltd. 43 Biotec Pharmacon ASA 44 Birken AG 45 Blueberry Therapeutics Ltd 46 Caladrius Biosciences, Inc. 47 Cellphire, Inc. 48 CorMedix, Inc. 49 Destiny Pharma Limited 50 FibroGen, Inc. 51 Foresee Pharmaceuticals, LLC 52 GangaGen Inc. 53 Gene Signal International SA 54 GlaxoSmithKline Plc 55 HanAll Biopharma Co., Ltd. 56 IntelliCell BioSciences Inc. 57 Juventas Therapeutics, Inc. 58 Kuros Biosurgery AG 59 LegoChem Biosciences, Inc 60 Living Cell Technologies Limited 61 Molecular Design International, Inc. 62 NatureWise Biotech & Medicals Corporation 63 Novan, Inc. 64 Nuvo Research Inc. 65 Octapharma AG 66 Omeros Corporation 67 Pacific Northwest Biotechnology, LLC 68 ProMetic Life Sciences Inc. 69 Regenics AS 70 RXi Pharmaceuticals Corporation 71 Sanofi 72 SomaGenics Inc. 73 Stratatech Corporation 74 Sucampo Pharmaceuticals, Inc. 75 Symic Biomedical, Inc. 76 TGV-Laboratories 77 Thesan Pharmaceuticals, Inc. 78 TumorEnd, LLC 79 VBS Pharmaceuticals 80 Vida Therapeutics Inc. 81 Wounds - Therapeutics Assessment 82 Assessment by Monotherapy Products 82 Assessment by Target 83 Assessment by Mechanism of Action 86 Assessment by Route of Administration 89 Assessment by Molecule Type 91 Drug Profiles 93 A-3APO - Drug Profile 93 Adipose Stem Cell Therapy for Skin Wound - Drug Profile 95 AG-30/5C - Drug Profile 96 AKB-4924 - Drug Profile 97 ALLO-ASC - Drug Profile 98 ANs-31 - Drug Profile 99 Antisense RNAi Oligonucleotide to Inhibit Fidgetin-like 2 for Wound Healing - Drug Profile 100 APO-2 - Drug Profile 101 AR-101 - Drug Profile 102 Arginine Butyrate - Drug Profile 103 ARN-077 - Drug Profile 104 ASCJ-9 - Drug Profile 105 Autologous Adipose Stem Cell Therapy for Diabetic Chronic Skin Wound - Drug Profile 107 Autologous Vascular Cells Therapy - Drug Profile 108 BB-1000 - Drug Profile 109 Biosimilar for Diabetic Wounds - Drug Profile 110 BKT-170 - Drug Profile 111 BTL-slo - Drug Profile 112 CAR Peptide - Drug Profile 113 Cell Therapy for Dermatology and Immunology - Drug Profile 114 Cell Therapy for Wounds - Drug Profile 117 CM-101 - Drug Profile 118 cobiprostone - Drug Profile 120 CR-2016 - Drug Profile 121 CRMD-004 - Drug Profile 122 CTR-2 - Drug Profile 123 daprodustat - Drug Profile 124 DB-2121 - Drug Profile 126 Drug for Dermatology and Infectious Diseases - Drug Profile 127 Drug to Antagonize Beta 2 Receptor for Wounds - Drug Profile 128 Drugs to Activate iRhom2 for Wound Healing and Cancer - Drug Profile 129 Drugs to Agonize c-Met for Wounds - Drug Profile 130 Drugs to Inhibit 11beta-HSD1 for Wound Healing - Drug Profile 131 FG-6874 - Drug Profile 132 FP-009 - Drug Profile 133 Gene Therapy to Activate HIF-1 Alpha for Wound and Ulcers - Drug Profile 134 GS-156 - Drug Profile 135 HL-156FIB - Drug Profile 136 Human Growth Factor - Drug Profile 137 hVGF - Drug Profile 138 JM-2 - Drug Profile 139 JVS-100 - Drug Profile 140 KL-7016 - Drug Profile 142 KUR-213 - Drug Profile 143 LCB-030110 - Drug Profile 144 LWnt-3a - Drug Profile 145 MDI-301 - Drug Profile 146 Mesenchymal Cells for Wound Care - Drug Profile 148 MG-53 - Drug Profile 149 MMP-26051 - Drug Profile 151 MMP-26052 - Drug Profile 152 Monoclonal Antibody Conjugated for Burns and Wounds - Drug Profile 153 Mul-1867 - Drug Profile 154 NBM-67 - Drug Profile 155 ND-336 - Drug Profile 156 NTCELL - Drug Profile 157 OleogelS-10 - Drug Profile 159 Oligomer G for Wounds And Burns - Drug Profile 161 Oxofoam - Drug Profile 162 P-128 - Drug Profile 163 Panaecin - Drug Profile 164 Pelladerm - Drug Profile 166 Peptide for Wounds - Drug Profile 167 perflenapent for wound healing - Drug Profile 168 Perlecan - Drug Profile 169 PGF - Drug Profile 171 plasminogen (recombinant) - Drug Profile 172 Polysaccharide for Wounds and Scars - Drug Profile 173 Protein for Diabetic Wound Healing - Drug Profile 174 Protein for Hematological Disorders, Dermatology, Shock and Injury - Drug Profile 175 Protein for Infectious Disease, Wounds and Skin Infections - Drug Profile 176 Protein to Activate FGFR for Dermatology, CNS, Cardiovascular and Musculoskeletal Disorders - Drug Profile 177 Protein to Inhibit SEB and TSST-1 for Infectious Disease, Dermatology, Respiratory Disorders and Other Diseases - Drug Profile 178 Recombinant Erythropoetin For Wounds, Bone Regeneration and Diabetic Ulcers - Drug Profile 179 Recombinant Protein to Activate Fibroblast Growth Factor for Wounds - Drug Profile 180 Recombinant Protein to Target MMP-9 for Wounds - Drug Profile 181 RNAi Oligonucleotide for Wound Healing - Drug Profile 182 Small Molecule to Target LGR6 for Wound Repair and Formation of New Hair Follicles - Drug Profile 183 Small Molecules for Wounds and Scars - Drug Profile 184 Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile 185 Soluble Beta Glucan - Drug Profile 186 Stem Cell Therapy for Wound Healing - Drug Profile 189 Synthetic Peptide to Antagonize CD168 for Respiratory, Dermatology, Oncology and Musculoskeletal Disorders - Drug Profile 190 Synthetic Peptide to Inhibit TIE-2 for Diabetic Foot Ulcers and Wounds - Drug Profile 192 Synthetic Peptides to Activate VEGF for Wound Healing and Neurodegenerative Diseases - Drug Profile 193 Synthetic Peptides to Antagonize TGF-Beta Receptor for Diabetic Foot Ulcers, Pulmonary Fibrosis and Dermatology - Drug Profile 194 Thrombosomes - Drug Profile 196 TRT-8174 - Drug Profile 197 ubidecarenone - Drug Profile 198 V-2248 - Drug Profile 200 Vernex - Drug Profile 201 VRP-017 - Drug Profile 202 VTI-3000 Series - Drug Profile 203 XF-70 - Drug Profile 204 Wounds - Recent Pipeline Updates 205 Wounds - Dormant Projects 216 Wounds - Discontinued Products 223 Wounds - Product Development Milestones 224 Featured News & Press Releases 224 Appendix 229 Methodology 229 Coverage 229 Secondary Research 229 Primary Research 229 Expert Panel Validation 229 Contact Us 229 Disclaimer 230
List of Tables
Number of Products under Development for Wounds, H2 2015 18 Number of Products under Development for Wounds - Comparative Analysis, H2 2015 19 Number of Products under Development by Companies, H2 2015 21 Number of Products under Development by Companies, H2 2015 (Contd..1) 22 Number of Products under Development by Companies, H2 2015 (Contd..2) 23 Number of Products under Development by Companies, H2 2015 (Contd..3) 24 Number of Products under Development by Companies, H2 2015 (Contd..4) 25 Number of Products under Investigation by Universities/Institutes, H2 2015 26 Number of Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 28 Comparative Analysis by Late Stage Development, H2 2015 29 Comparative Analysis by Clinical Stage Development, H2 2015 30 Comparative Analysis by Early Stage Development, H2 2015 31 Comparative Analysis by Unknown Stage Development, H2 2015 32 Products under Development by Companies, H2 2015 33 Products under Development by Companies, H2 2015 (Contd..1) 34 Products under Development by Companies, H2 2015 (Contd..2) 35 Products under Development by Companies, H2 2015 (Contd..3) 36 Products under Development by Companies, H2 2015 (Contd..4) 37 Products under Investigation by Universities/Institutes, H2 2015 38 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 39 Wounds - Pipeline by Advancell, H2 2015 40 Wounds - Pipeline by Aerpio Therapeutics, Inc., H2 2015 41 Wounds - Pipeline by AlgiPharma AS, H2 2015 42 Wounds - Pipeline by AndroScience Corporation, H2 2015 43 Wounds - Pipeline by AnGes MG, Inc., H2 2015 44 Wounds - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 45 Wounds - Pipeline by Beech Tree Labs, Inc., H2 2015 46 Wounds - Pipeline by Berg LLC, H2 2015 47 Wounds - Pipeline by Bio3 Research S.r.l, H2 2015 48 Wounds - Pipeline by Biokine Therapeutics Ltd., H2 2015 49 Wounds - Pipeline by Biotec Pharmacon ASA, H2 2015 50 Wounds - Pipeline by Birken AG, H2 2015 51 Wounds - Pipeline by Blueberry Therapeutics Ltd, H2 2015 52 Wounds - Pipeline by Caladrius Biosciences, Inc. , H2 2015 53 Wounds - Pipeline by Cellphire, Inc., H2 2015 54 Wounds - Pipeline by CorMedix, Inc., H2 2015 55 Wounds - Pipeline by Destiny Pharma Limited, H2 2015 56 Wounds - Pipeline by FibroGen, Inc., H2 2015 57 Wounds - Pipeline by Foresee Pharmaceuticals, LLC, H2 2015 58 Wounds - Pipeline by GangaGen Inc., H2 2015 59 Wounds - Pipeline by Gene Signal International SA, H2 2015 60 Wounds - Pipeline by GlaxoSmithKline Plc, H2 2015 61 Wounds - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 62 Wounds - Pipeline by IntelliCell BioSciences Inc., H2 2015 63 Wounds - Pipeline by Juventas Therapeutics, Inc., H2 2015 64 Wounds - Pipeline by Kuros Biosurgery AG, H2 2015 65 Wounds - Pipeline by LegoChem Biosciences, Inc, H2 2015 66 Wounds - Pipeline by Living Cell Technologies Limited, H2 2015 67 Wounds - Pipeline by Molecular Design International, Inc., H2 2015 68 Wounds - Pipeline by NatureWise Biotech & Medicals Corporation, H2 2015 69 Wounds - Pipeline by Novan, Inc., H2 2015 70 Wounds - Pipeline by Nuvo Research Inc., H2 2015 71 Wounds - Pipeline by Octapharma AG, H2 2015 72 Wounds - Pipeline by Omeros Corporation, H2 2015 73 Wounds - Pipeline by Pacific Northwest Biotechnology, LLC, H2 2015 74 Wounds - Pipeline by ProMetic Life Sciences Inc., H2 2015 75 Wounds - Pipeline by Regenics AS, H2 2015 76 Wounds - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 77 Wounds - Pipeline by Sanofi, H2 2015 78 Wounds - Pipeline by SomaGenics Inc., H2 2015 79 Wounds - Pipeline by Stratatech Corporation, H2 2015 80 Wounds - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015 81 Wounds - Pipeline by Symic Biomedical, Inc., H2 2015 82 Wounds - Pipeline by TGV-Laboratories, H2 2015 83 Wounds - Pipeline by Thesan Pharmaceuticals, Inc., H2 2015 84 Wounds - Pipeline by TumorEnd, LLC, H2 2015 85 Wounds - Pipeline by VBS Pharmaceuticals, H2 2015 86 Wounds - Pipeline by Vida Therapeutics Inc., H2 2015 87 Assessment by Monotherapy Products, H2 2015 88 Number of Products by Stage and Target, H2 2015 90 Number of Products by Stage and Mechanism of Action, H2 2015 93 Number of Products by Stage and Route of Administration, H2 2015 96 Number of Products by Stage and Molecule Type, H2 2015 98 Wounds Therapeutics - Recent Pipeline Updates, H2 2015 211 Wounds - Dormant Projects, H2 2015 222 Wounds - Dormant Projects (Contd..1), H2 2015 223 Wounds - Dormant Projects (Contd..2), H2 2015 224 Wounds - Dormant Projects (Contd..3), H2 2015 225 Wounds - Dormant Projects (Contd..4), H2 2015 226 Wounds - Dormant Projects (Contd..5), H2 2015 227 Wounds - Dormant Projects (Contd..6), H2 2015 228 Wounds - Discontinued Products, H2 2015 229
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
